**Table S1:** The impact of Bromadiolone, Aspirin and combination of Aspirin and Bromadiolone on **Heamatological parameters** in rodents (Wild Rats); the sign (•) is used to show non-significant p ˃ 0.05, the sign (\*) is used to show significant difference for control group with p ˂ 0.05 and the sign (°) is used to show significant difference for bromadiolone group with p ˂ 0.05.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter | Control | Bromadiolone | Aspirin | Aspirin+Bromadiolone |
| RBCs (x106/UL | 5.36 ±0.393 | 6.23 ±0.758 • | 3.67 ±0.363 \*° | 5.5 ±1.489 •• |
| Hemoglobin (g/dl) | 14.15 ±0.455 | 13.32 ±0.778• | 10.98 ±0.778\*° | 13.97 ±1.587•• |
| Hematocrit (%) | 39.75 ±1.856 | 38.63 ±2.478• | 35.43 ±1.453\*° | 38.88 ±1.83 •• |
| MCV (fL) | 66.08 ±4.077 | 60.93 ±3.676• | 57.85 ±2.347\*° | 65.12 ±2.579 •• |
| MCH (Pg) | 23.57 ±1.592 | 25.5 ±3.344• | 20.84 ±1.035\*° | 23.33 ±1.8 •• |
| MCHC (g/dL) | 35.65 ±1.412 | 37.93 ±2.876• | 32.85 ±2.029\*° | 37.38 ±2.646 •• |
| RDW-CV (%) | 11.97 ±0.294 | 12.12 ±0.621• | 13.6 ±0.94\*° | 12.08 ±0.407 •• |
| RDW-SD (fL) | 38.05 ±1.936 | 36.13 ±2.132• | 32.23 ±1.716\*° | 36.07 ±3.257 •• |
| Platelets (103/UL) | 299.33 ±51.212 | 320.5 ±35.07• | 411 ±23.707\*° | 283.5 ±72.946 •• |
| PCT (%) | 0.05 ±0.014 | 0.04 ±0.003• | 0.03 ±0.004\*° | 0.04 ±0.006 •• |
| MPV (fL) | 7.27 ±0.103 | 7.16 ±0.697• | 8.13 ±0.518\*° | 7.23 ±0.52 •• |
| PDW (fL) | 11.98 ±0.426 | 11.77 ±0.997• | 14.85 ±1.795\*° | 11.63 ±0.937 •• |
| WBCs (x103/uL) | 5.08 ±0.789 | 4.79 ±1.161• | 7.84 ±1.474\*° | 4.89 ±1.289 •• |
| Neutrophils (%) | 10.65 ±3.705 | 12 ±1.432• | 21.73 ±3.404\*° | 12.05 ±1.152 •• |
| Lymphocytes (%) | 76.62 ±5.293 | 73.93 ±2.284• | 70.29 ±3.101\*° | 74.93 ±2.835 •• |
| Monocytes (%) | 11.73 ±2.352 | 13.07 ±3.397• | 6.98 ±1.008\*° | 12.02 ±2.717 •• |
| EOS (%) | 0.59 ±0.118 | 0.65 ±0.17• | 0.35 ±0.05\*° | 0.6 ±0.136 •• |
| Bas (%) | 0.04 ±0.007 | 0.04 ±0.01• | 0.02 ±0.003\*° | 0.04 ±0.008•• |

**Table S2:**  The impact of Bromadiolone, Aspirin and combination of Aspirin and Bromadiolone on **hemostatic parameters** in rodents (Wild Rats)**; the sign (•)** is used to show non-significant p ˃ 0.05, the sign (**\***) is used to show significant difference for control group with p ˂ 0.05 and the sign (**°**) is used to show significant difference for bromadiolone group with p ˂ 0.05.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter | Control | Bromadiolone | Aspirin | Aspirin+Bromadiolone |
| Bleeding Time (min: sec) | 0.46 ±0.014 | 0.5 ±0.05• | 1.61 ±0.131\*° | 0.55 ±0.115•• |
| Clotting Time (min:sec) | 1.45 ±0.11 | 1.33 ±0.182• | 3.04 ±0.092\*° | 1.53 ±0.066•° |
| Prothrombin Time (sec) | 14.79 ±1.238 | 13.51 ±1.556• | 21.51 ±1.487\*° | 15.96 ±3.626•• |
| Ca+2(nmoL/L) | 0.74 ±0.052 | 0.7 ±0.031• | 0.62 ±0.025\*° | 0.72 ±0.044•• |
| Factor VII (%) | 45.13 ±0.497 | 42.58 ±3.268• | 138.33 ±1.506\*° | 48.17 ±3.656•° |
| Factor IX (%) | 89.67 ±0.849 | 90.08 ±0.467• | 159.6 ±0.498\*° | 90.38 ±0.842•• |

**Table 3:** The impact of Bromadiolone, Aspirin and combination of Aspirin and Bromadiolone on **oxidative stress parameters** in rodents (Wild Rats); the sign (•) is used to show non-significant p ˃ 0.05, the sign (\*) is used to show significant difference for control group with p ˂ 0.05 and the sign (°) is used to show significant difference for bromadiolone group with p ˂ 0.05.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter | Control | Bromadiolone | Aspirin | Aspirin+Bromadiolone |
| Catalase activity (U /ml) | 105.21 ±6.85 | 89.84 ±3.79\* | 107.6 ±4.288͘͘•° | 104.34 ±11.522•° |
| SOD activity (U /ml) | 110.58 ±8.227 | 63.63 ±3.447\* | 117.23 ±1.654•° | 79.51 ±2.615\*° |
| Glutathione activity (U /ml) | 105.32 ±3.412 | 92.31 ±0.73\* | 116.58 ±3.633\*° | 103.36 ±3.17•° |
| Lipid peroxide level (nmol /ml) | 59.54 ±4.176 | 43.69 ±3.407\* | 84.03 ±2.421\*° | 53.11 ±2.011\*° |